Effect of GLP-1 receptor agonist in combination with insulin on abdominal fat in patients with type 2 diabetes trial

Effect of GLP-1 receptor agonist in combination with insulin on abdominal fat in patients with type 2 diabetes trial - GLP-1 receptor agonist and abodominal fat in diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015867

Enrollment

100

Registered

2014-12-15

Start date

2014-12-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with type 2 diabetes

Interventions

Liraglutide 0.9 mg added to insulin treatment insulin alone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients treated with insulin whose HbA1c levels are between 7 and 10% and BMI levels are> or = 25 kg/m2

Exclusion criteria

Exclusion criteria: Type 1 diabetes Patients with allergy to incretin mimetics Patients with interstitial pneumonia Patints with liver chirrosis or renal failure Patients who had experienced acute coronary syndrome or stroke or acute pancreatitis within 3 months prior to enrollment Patients with malignant neoplasms Patients who are alread treated with DPP4 inhibitors and/or GLP-1 receptor agonists. Patients whose dosage of insulin has been changed by > 20 % within 3 months prior to enrollment

Design outcomes

Primary

Measure	Time frame
The change in visceral fat area 24 after administration of liraglutide	—

Secondary

Measure	Time frame
The change in liver attenuation index 24 after administration of liraglutide	—

Countries

Japan

Contacts

Public ContactRyotaro Bouchi

Tokyo Medical and Dental University Departmet of Molecular Endocrinology and Metabolism

bouchi.mem@tmd.ac.jp03-3813-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026